/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

ZENAS BIOPHARMA INC share price today is $24.5, up -3.31%. The stock opened at $25.1 against the previous close of $25.34, with an intraday high of $25.35 and low of $23.97.

style

pb-0

ZENAS BIOPHARMA INC

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$24.5 -0.0331(-3.31%) ZBIO at 13 Mar 2026 04:00 PM Biotechnology

Lowest Today 23.97

Highest Today 25.35

Today’s Open 25.1

Prev. Close 25.34

52 Week High 44.60

52 Week Low 6.11

Day’s Range: Low 23.97 High 25.35

52-Week Range: Low 6.11 High 44.60

ZENAS BIOPHARMA INC Institutional Holdings

ZENAS BIOPHARMA INC Market Status

Strong Buy: 5

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

ZENAS BIOPHARMA INC Fundamentals

Market Cap 1914.20 M

PB Ratio 7.0915

PE Ratio 2.6086

Enterprise Value 1070.14 M

Total Assets 369.97 M

Volume 294050

ZENAS BIOPHARMA INC Company Financials

About ZENAS BIOPHARMA INC & investment objective

Company Information Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; and ZB001, an anti-IGF-1R monoclonal antibody. The company was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is headquartered in Waltham, Massachusetts.

Organisation Biotechnology

Employees 130

Industry Biotechnology

CEO Mr. Leon Oliver Moulder Jr., M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*